Companies that want to play in rare diseases need to shop for gene therapies, but price tags are looking rich.
Limiting abuse and reducing risks are the differentiating factors for projects from Kempharm and Supernus.
Bristol-Myers Squibb is ahead in a new oral class that could bring similar efficacy to current injectables for autoimmune diseases – but Pfizer seems less keen.
A genome editing tie-up between Gilead and Precision Biosciences, and promising early data with Arrowhead’s RNA interference project, are two novel approaches in hep B.
Chi-Med is not alone in seeing Chinese approval as the prelude to a regulatory green light in the west.
The companies have taken a different label-expansion approach to rivals Johnson & Johnson and Bayer, but all are hoping for a win in cancer patients.
The industry has its work cut out to rebuild trust in the tech following doubts about one pioneer, IBM Watson.
Novartis hails the most advanced alpha-directed PI3K inhibitor after success in breast cancer, but it’s not the only one.
Since becoming a pure-play health tech group Philips has been buying like crazy. Might Siemens Healthineers and GE Healthcare join in?